Goodpasture Syndrome clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Imlifidase in Anti-GBM Disease
Sorry, in progress, not accepting new patients
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
Los Angeles, California and other locations
Our lead scientists for Goodpasture Syndrome research studies include Suphamai Bunnapradist, MD, MS.
Last updated: